A founder may walk into an IPO meeting with strong revenue growth, a full order book and an ambitious expansion plan. The first serious investor question can still be simple: Can you prove that every product, facility and process is authorised, controlled and ready to scale?
For a healthcare or pharma SME, IPO readiness lives in the evidence behind the story. Licences must match the products and sites that generate revenue. Quality systems must produce records that withstand diligence. Growth metrics must show cash generation, operating discipline and a credible use of proceeds.
Let’s look at what founders should prepare before the IPO process gets serious.
Build a Licence Register That Matches the Business
Start with a register organised by product, legal entity, activity and site.
For each entry, record the issuing authority, licence number, approved scope, issue date, renewal or retention status, conditions, responsible owner and evidence location. Include manufacturing, loan-licence, import, wholesale, clinical or investigational, pollution-control, factory and other site-specific permissions where relevant.
Drug regulation in India is shared between central and state authorities. Central functions include areas such as drug approvals, clinical trials, standards and imported-drug quality, while state regulators perform significant licensing and enforcement functions. Certain categories, including blood products, vaccines, sera and IV fluids, can involve joint licensing routes.
A central approval should therefore sit inside a complete state and local permissions map. Do not assume that one approval covers every product, plant or activity carried out by the company.
For a drug manufacturer, reconcile each marketed product and manufacturing site to the applicable licence, approved product list, premises details and current regulatory correspondence. Pharmaceutical manufacturing applicants must meet the applicable Good Manufacturing Practices requirements in Schedule M.
For medical-device and in-vitro-diagnostic businesses, map each product to its risk class, intended use and applicable route under the Medical Devices Rules, 2017. One certificate or approval should never be assumed to cover an entire portfolio.
A useful test: If a product generates revenue, the team should be able to show exactly which approval allows it to be made, imported, sold or distributed.
Bottom line: Your licence register should explain what is approved, where it is approved, who owns the renewal and which revenue depends on it.
Make Quality Systems Visible in Daily Records
A quality system earns investor confidence through everyday evidence.
Keep controlled SOPs, training records, equipment qualification, calibration, cleaning and process validation, master manufacturing records, batch records, laboratory results, stability data, supplier qualification, change control, deviation and out-of-specification investigations, CAPA, complaints, recalls and management reviews.
Document control should show who approved a record, when the activity occurred, which batch or transaction it relates to, and whether any change can be traced. Electronic systems need role-based access, change history, backup and retrieval evidence.
Distribution records should support batch and expiry traceability, with controls for quarantined, returned, rejected and recalled stock.
Create one controlled log for deviations, complaints, inspection observations, returns, recalls and regulatory notices. Each item needs a risk assessment, root-cause analysis, owner, due date, corrective action, effectiveness check and closure approval.
Report ageing, repeat and high-risk items to management. A certificate can support the file. Consistent records show that the system works.
Bottom line: Investors trust quality systems when the records show what happened, who reviewed it and how the issue was closed.
Create an IPO Evidence File
The data room should connect every material licence to its scanned approval, renewal filing, inspection history, response and current business impact.
Reconcile the register to revenue by product, plant and location. Flag expired, conditional, suspended, disputed or soon-to-expire permissions, along with any product made outside approved scope.
Include inspection reports, show-cause notices, recall or adverse-event matters, litigation, statutory dues and remediation plans. Maintain a red-flag log with an owner, target date and disclosure recommendation.
Public-offer preparation requires attention to securities, company and industry-specific laws. Continued operations do not remove the need to assess a regulatory issue for disclosure.
For hospitals, clinics, laboratories and diagnostic centres, verify the applicable clinical-establishment registration, fire, building, pharmacy, radiology, biomedical-waste and local permissions for every location. The central clinical-establishments framework does not apply uniformly across all states and Union Territories.
Biomedical-waste authorisation, treatment-facility contracts, segregation logs, staff training and reporting records should sit in the same evidence file.
Keep a separate red-flag register for:
- Expired or mismatched licences
- Products made outside approved scope
- Unresolved inspection observations
- Overdue CAPA
- Product complaints or recalls
- Show-cause notices and regulatory correspondence
- Revenue that depends on a pending approval
- Licences that are non-transferable or close to expiry
Bottom line: A clean IPO data room should make regulatory gaps easy to find, explain and track to closure.
Present Growth Metrics Investors Can Test
Financial quality
Begin with three to five years of audited revenue, revenue CAGR, gross margin, EBITDA, EBITDA margin, PAT, operating cash flow, free cash flow to equity, ROCE, leverage and working-capital days.
Reconcile every adjusted measure to the audited statements. Explain exceptional costs, promoter transactions, subsidies and tax effects in plain language.
Revenue quality
Show revenue by product, therapy or device category, geography, domestic versus export, customer and channel. Add top-five customer concentration, related-party sales, repeat-order rate, tender dependence, price-volume mix and newly launched product share.
Track receivable days, inventory ageing, expiry or slow-moving stock, payable days, capex intensity and the cash conversion cycle. A fast-growing pharma business that funds growth through overdue receivables or excess inventory needs a clear correction plan.
Operating control
Operational metrics should connect growth with quality and delivery:
- Capacity utilisation
- Batch right-first-time rate
- Rejection or rework rate
- Complaints and recalls
- CAPA ageing
- On-time-in-full delivery
- Supplier qualification status
- Training completion
- Calibration and preventive-maintenance compliance
Define the population, period, owner and calculation method for every KPI.
Published NSE Emerge criteria currently include an operating-profit screen of at least ₹1 crore from operations in any two of the preceding three financial years, positive net worth and positive free cash flow to equity in at least two of those three years.
Treat these as eligibility screens, subject to confirmation at filing. They are not a valuation benchmark or a promise that the issue will succeed.
Bottom line: Strong growth is easier to defend when revenue, cash flow, capacity and quality metrics all point in the same direction.
Illustrative Example: Aarohi Therapeutics
Aarohi Therapeutics is a fictional oral-solid-dosage manufacturer. It reports strong sales growth and plans to use IPO proceeds for a second production line.
Its readiness review finds that revenue is concentrated in two distributors, one product variation is awaiting approval, three CAPAs are overdue and inventory days have risen sharply.
The management team builds a site and product licence matrix, links each product to batch and stability records, closes or escalates the overdue CAPAs, runs a mock recall and separates approved revenue from pipeline revenue.
The investor dashboard then shows capacity, customer concentration, cash conversion, quality trends, renewal dates and use-of-proceeds milestones. The story becomes easier to trust because each claim has an owner and a source record.
That is what a good readiness exercise should do. It should bring the gaps into the open while there is still time to fix them.
Bottom line: The goal is not a perfect presentation. It is a business story that can be checked against its records.
Founder Checklist and Next Step
Before appointing the merchant banker, run a review across operations, quality, finance, legal and regulatory teams.
Healthcare and pharma IPO readiness checklist:
- Licences: Does every product, site and activity have a current, in-scope approval?
- Quality: Can the team retrieve a complete batch, complaint or recall file quickly?
- Regulatory risk: Are notices, inspections, CAPA and renewals logged with owners and dates?
- Financial quality: Do revenue, EBITDA, cash flow, receivables and inventory reconcile?
- Growth: Are capacity, customers, pipeline and IPO proceeds tied to measurable outcomes?
- Disclosure: Have legal, finance, quality and regulatory leaders reviewed the evidence trail?
Refresh this review monthly through filing. Keep the dashboard linked to the underlying records, not only to a presentation prepared for investor meetings.
If you are working through this process, ValuGenius Advisors LLP can help organise the readiness dashboard, connect operating evidence to the financial story, and identify questions that need specialist regulatory or IPO advice.
ValuGenius is a Mumbai-based valuation and financial advisory firm supporting startups, SMEs, corporates and investors with business valuation, startup valuation, FEMA valuation, Ind AS valuation, M&A valuation and financial modelling.
Final Thoughts
For a healthcare or pharma SME, IPO readiness is built long before the prospectus is drafted.
It starts with a licence register that matches the real business. It continues with quality records that can withstand scrutiny. It becomes credible when revenue, cash flow, capacity and growth plans all tell the same story.
Founders should not wait for a diligence request to discover that a renewal is overdue, a CAPA is still open or a product approval does not cover the site where the product is made.
Prepare the evidence early. Review it regularly. Keep every claim tied to a record.
That makes the IPO conversation clearer for the founders, the merchant banker and the investors.